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Abstract: This study began with the goal of identifying constituents from Zyzzya fuliginosa extracts
that showed selectivity in our primary cytotoxicity screen against the PANC-1 tumor cell line. During
the course of this project, which focused on six Z. fuliginosa samples collected from various regions
of the Indo-Pacific, known compounds were obtained consisting of nine makaluvamine and three
damirone analogues. Four new acetylated derivatives were also prepared. High-accuracy electrospray
ionization mass spectrometry (HAESI-MS) m/z ions produced through MS2 runs were obtained and
interpreted to provide a rapid way for dereplicating isomers containing a pyrrolo[4,3,2-de]quinoline
core. In vitro human pancreas/duct epithelioid carcinoma (PANC-1) cell line IC50 data was obtained
for 16 compounds and two therapeutic standards. These results along with data gleaned from
the literature provided useful structure activity relationship conclusions. Three structural motifs
proved to be important in maximizing potency against PANC-1: (i) conjugation within the core
of the ABC-ring; (ii) the presence of a positive charge in the C-ring; and (iii) inclusion of a 4-ethyl
phenol or 4-ethyl phenol acetate substituent off the B-ring. Two compounds, makaluvamine J (9)
and 15-O-acetyl makaluvamine J (15), contained all three of these frameworks and exhibited the best
potency with IC50 values of 54 nM and 81 nM, respectively. These two most potent analogs were
then tested against the OVCAR-5 cell line and the presence of the acetyl group increased the potency
14-fold from that of 9 whose IC50 = 120 nM vs. that of 15 having IC50 = 8.6 nM.
Keywords: makaluvamine; Zyzzya fuliginosa; marine sponge; MS-MS fragmentation profiling;
PANC-1 and OVCAR-5 cytotoxicity
1. Introduction
A priority in our study of marine-derived alkaloids has been to explore bioactive products isolable
from both sponges and microorganisms. Exploring such molecules offers the prospect of rapidly
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Mar. Drugs 2017, 15, 98 2 of 18
assembling multi-compound libraries for comprehensive bioactivity and biosynthetic investigations.
High profile, contemporary examples of such campaigns include studies from our lab and from others
involving bioactive entities, such as: (i) bengamides from sponges (Jaspis coriacea) [1] and Gram-negative
bacteria (Myxococcus virescens) [2,3]; (ii) manzamines from sponges (Acanthostrongylophora sp.) [4]
and Gram-positive bacteria (Micromonospora sp. strain M42) [5]; and (iii) onnamide A from sponges
(Theonella swinhoei, yellow chemotype) [6] and the sponge-associated Candidatus entotheonella [7].
Motivated by the potential to expand on this circumstance we began a deep examination of Zyzzya
sponge metabolites to further assess their bioactivity and to design future experiments that probe the
potential of this sponge as a source of chemically prolific bacteria.
During expeditions to multiple Indo-Pacific sites, our attention was repeatedly drawn to
Zyzzya fuliginosa, a ubiquitous, black burrowing sponge that exudes black mucus on collection.
Z. fuliginosa reliably affords compounds possessing the pyrrolo[4,3,2-de]quinoline core shown in
Figure 1. Two years ago several specimens in our repository were flagged for a priority study when a
methanol extract fraction of Z. fuliginosa (coll. No. 93132 DMM) obtained from Papua New Guinea
exhibited potent and selective in vitro cytotoxic activity against the human pancreas/duct epithelioid
carcinoma (PANC-1) cell line. Solvent partitioning of the crude extract concentrated the activity into a
highly pigmented methanol fraction whose 1H-NMR spectrum displayed low-field singlets at δ 7.3/δ
6.3 and upfield A2X2 multiplets δ 3.8/δ 2.9 characteristic of makaluvamines [8–15]. We recognized
that: (i) the initial lead bioactive compounds of this family (Figure 1) were reported decades ago;
makaluvamine A (1) in 1993 [8,9], and discorhabdins A-C in 1986 [13]; and (ii) no such analogs have
been evaluated in human clinical trials. The paucity of pancreatic cancer selective agents useful as either
therapeutic leads or clinical agents motivated our exploratory work to isolate Z. fuliginosa constituents
and then prepare new semi-synthetic analogs of the most active makaluvamines. The major goal was
to identify one or more potent (low nanomolar active) compounds active against pancreatic tumor
cell lines.
At an early stage in the project we sought understanding on the scope of natural
“makaluvamine-type” scaffolds known from the marine and terrestrial environment. Highlights
of important patterns shown in Figure 1 are organized around compounds containing the C10N2
pyrrolo[4,3,2-de]quinoline. This framework is now considered to be created by ribosomally synthesized
and post-translationally modified peptide (RiPP) pathways delivering a C-terminal tryptophan
building block [16]. The compilation in Figure 1 also abstracts therapeutic assessment outcomes
for eight different lead structures [8–15,17–22]. Two sponge genera, Zyzzya and Latrunculia, [23] are
abundant sources of pyrrolo[4,3,2-de]quinolines which now number close to 100 structures. To date
only one compound, wakayin [15], has been isolated from a tunicate. Additionally, five of the
molecules in Figure 1 are products of biosynthetic machinery present in microorganisms. Most notably,
makaluvamine A (1) repeatedly isolated from Zyzzya [23] has also been reported from a terrestrial
slime mold [10]. Mushrooms produce further functionalized core skeletons represented by sanguinone
A [18] and mycenarubin A [17]. Marine-derived Gram-positive microorganisms are the source of:
(a) ammosamides [19,20] possessing halogen substituents; and (b) lymphostins [21,22] containing
additional residues created by PKS biosynthesis. While several of the compounds in Figure 1 inhibit
druggable cancer targets few of them shown here or elsewhere exhibit single or double digit nanomolar
in vitro potency.
Many of the natural pyrrolo[4,3,2-de]quinolines (Figure 1) and the more than 80 designed synthetic
analogues prepared to date [23] show interesting therapeutic potential. Inexplicably, none of these
compounds are under current pre-clinical investigations even though great promise was expressed in
2005 by the National Cancer Institute—U. Utah collaborative study [9] which contained the following
passages: “The makaluvamines promote topoisomerase II DNA cleavage in vitro.” and “There may be
yet other mechanisms of action involved in the antitumor activity of the pyrroloiminoquinones . . .
makaluvamine H and I may warrant further in vivo evaluations in a broader panel of solid tumors.”
Overall, the lack of recent forward progress in the pre-clinical investigation of these compounds is
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dismaying; especially in light of evidence showing that their anti-tumor activity may be via mechanisms
beyond topoisomerase II inhibition [24].
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Figure 1. A summary of similar natural products containing the C10N2 pyrrolo[4,3,2-de]quinoline core
along with their sources (S) and therapeutic potential (TP).
Motivated by the positive PANC-1 selective data for the Z. fuliginosa (coll. No. 93132) extract,
we searched for additional literature data. These surveys revealed four pyrrolo[4,3,2-de] quinolines:
isobatzelline A, C, D, and secobatzelline A from a Caribbean Batzella sp. of sponge [23], and one
synthetic analog, FBA-TPQ (7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de] quinolin-
8(1H)-one) [25] which displayed moderate cytotoxicity against PANC-1 cells. Thus far, there have been
no comprehensive studies on the makaluvamines evaluating their cytotoxicity against PANC-1 cells;
however the pyrrolo[4,3,2-de]quinoline, isobatzellin C, a poor topoisomerase II inhibitor exhibited
an IC50 of 10 µM against PANC-1 [26]. We now describe the isolation, structure modification, and
bioactivity assessment of nine makaluvamines, three damirones, and four new semi-synthetic acetate
esters. Once the structures of this collection were established we obtained data against PANC-1 and
OVCAR-5 cell lines to establish a structure in vitro cytotoxicity activity relationship for this class of
molecules. We discuss below the rationale and possible next steps for the further development of these
compounds as therapeutic leads.
2. Results
The experimental design employed in this study involved the assembly of a small compound
library consisting of natural and semi-synthetic pyrrolo[4,3,2-de]quinolines for additional study of their
potential as leads for marine derived anti-cancer drugs. For decades the major mechanism of action for
this class has been repeatedly described as involving topoisomerase II inhibition, which has dampened
enthusiasm for their further study. The new twist here involved assembling a library of compounds
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for detailed evaluation as selective cytotoxins that could involve different molecular targets. Even
though no new natural analogues were being pursued in our study it appeared productive to further
explore bioassay properties of the pyrrolo[4,3,2-de]quinolines by further functionalizing the amino side
chain with various substituents. Such structures are analogous to the family of TPQ synthetic analogs
extensively explored by Velu and Zhang [27] whose properties relative to those of the makaluvamines
will be further discussed below.
2.1. The Isolation Campaign
We began in this study with a focused re-investigation of Zyzzya sponges in order to isolate and
re-screen makaluvamines C, H, and I described in 2005 [9] as “most potent and differential.” Of further
relevance to this plan is that two of these compounds exhibited promising in vivo T/C% (tumor volume
in treated/tumor volume in untreated) in KB mouse model xenografts (H = 38%, I = 34%) [9]. Since
that publication none of these compounds or other natural congeners have been further investigated.
Consequently, we formulated a campaign to obtain this trio of compounds. A second goal was
to explore a University of California Santa Cruz (UCSC) repository sample (Z. fuliginosa, coll.
No. 93132) having semi-pure fractions with PANC-1 selective cytotoxicity. Its methanol-soluble
fraction (coded DMM) exhibited an inhibitory zone differential of 8 cm between PANC-1 cells and
“normal” CFU-GM cells at 180 µg per disk. NMR and LCMS evaluation of the crude extracts implied
that four compounds could be obtained including makaluvamines C (2), D (7), J (9), and damirone A
(5). While a multi-milligram sample of makaluvamine H (4) was available from the UCSC repository,
there were no samples of makaluvamine I available.
Isolation work on the sample (collection number 93132) described above provided 10 mg of
makaluvamine C (9). We were convinced that other compounds could be efficiently obtained once a
repertoire of makaluvamine-containing Z. fuliginosa sponges was assembled. This was successfully
achieved and summarized in Figure 2 along with a representative underwater photograph of
Z. fuliginosa. There were 33 samples in total; the UCSC repository was the source of 15 of these
and 18 were provided from the National Cancer Institute-Developmental Therapeutics Program
(NCI-DTP) branch. Overall, these sponges were collected from more than four major Indo-Pacific
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Figure 2. Zyzzya fuliginosa sponges for the isolation campaign of their cytotoxic pyrrolo[4,3,2-de]
quinoline constituents (1–12). Six of the 33 repository samples available were extensively investigated
using * UCSC and # NCI-DTP material.
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The work flow on the six samples shown in Figure 2 proceeded uneventfully and subsequently
provided known compounds 1–12 (Figure 3) all containing the pyrrolo[4,3,2-de]quinoline core
(Figure 1). Details of the isolation results are shown in Supplementary Materials Schemes
S1–S5. Highlights of the dereplication steps including 1H-NMR and MS2 data will be discussed
later. The sustained work on these samples provided large multi-milligram quantities of four
compounds: makaluvamine C (2) = 72 mg, damirone B (3) = 102 mg, makaluvamine D (7) = 61 mg,
and makaluvamine J (9) = 118 mg. Smaller amounts of seven compounds were also obtained:
makaluvamine A (1) = 30 mg, damirone A (5) = 14 mg, damirone D (6) = 4 mg, makaluvamine
G (8) = 14 mg, makaluvamine K (10) = 38 mg, makaluvamine L (11) = 11 mg, and makaluvamine
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Figure 3. Pyrrolo[4,3,2-de]quinoline containing natural products screened against the PANC-1
cell line in this study consisting of: (i) makaluvamines A (1), C (2), H (4), D (7), G (8), J-L
(9–11), P (12); (ii) damirones A (5), B (3), D (6); (iii) semisynthetic makaluvamine acetates
9-N-acetyl makaluvamine A (13), 9-N-acetyl makaluvamine B (14), 15-O-acetyl makaluvamine J (15),
8,15-O-diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J (16); and (iv) ammosamide B (17).
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2.2. Dereplicating Pyrrolo[4,3,2-de]quinolines Using MS2 Patterns
Employing only 1H-NMR data to engage in rapid dereplication of a pyrrolo[4,3,2-de]quinolines
can be challenging. The major problem is that the resonances that might be used to characterize the
core skeleton are not rich with information. Signals for five to six distinct protons assignable to this
core (Table S1) are either singlet or triplet resonances, which does not allow making interconnections
between isolated spin systems. Consequently, we sought data from high accuracy electrospray
ionization mass spectrometry (HAESI-MS) m/z ions produced through MS2 runs. Aside from a lone
MS-MS study on synthetic makaluvamine analogs FBA-TPQ/PEA-TPQ [25] no such data can be found
in the literature. Consequently, as each compound was purified and analyzed by 1H-NMR the dataset
was expanded to include MS2 analysis. Typical results are shown in Scheme 1 and diagnostic patterns
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represent  a  signature  fingerprint.  The  panels  (a,  c)  illustrate  fragmentations  for  the 
iminocyclohexadienones (examples MAK C (2) and MAK J (9)) and panel (b) shows fragmentation 
for the animocyclohexadienediones (example DAM A (5)). 
Scheme 1. Makaluvamine and damirone MS2 fragmentation ions diagnostic for N-alkyl substitutions
for the pyrolo[4,3,2-de]quinoline core family. Annotated peaks, especially intense m/z ions
in bold, represent a signature fingerprint. The panels (a, c) illustrate fragmentations for the
iminocyclohexadienones (examples MAK C (2) and MAK J (9)) and panel (b) shows fragmentation for
the animocyclohexadienediones (example DAM A (5)).
Distinct MS2 fingerprints (Scheme 1) resulted from the loss of specific functional groups from the
parent ions depending on the class of compound. The functional groups were coded with specific
letters (A–N) and the MS2 peaks that correspond to the parent mass minus that functional group
are labeled with that letter code. There were four distinct MS2 fingerprints that arose from 1 to 12.
The first was observed from the makaluvamines that did not contain a N-aryl phenol substituent off
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the B-ring, makaluvamines A (1), C (2), and H (4) (Scheme 1a). These compounds generated MS2
fragments that corresponded to the loss of the following functional groups: CH3• (A), CH4 (B), NH3
(C), H2O (D), HCN (E), CH3CN (F), and CH3NO (G). The most intense of which were the loss of C
from 1, E from 2, and B from 4. The second fingerprint observed was from damirones B (3), A (5),
and D (6) (Scheme 1b), these compounds generated fragments that resulted from the loss of similar
groups as the makaluvamines A (1), C (2), and H (4), such as A, B, D, and F. However, the most
intense fragments resulted from the loss of CO (H) and CH2O2 (I), two fragmentation ions that did
not arise from any of the makaluvamine analogs and were diagnostic of the damirone ring core. The
third MS2 fingerprint observed was from the makaluvamines with a 4-ethyl phenol substituent off the
B-ring, D (7), J (9), K (10), and P (12) (Scheme 1c). These compounds had identical MS2 fingerprints
that arose from the loss of CH3N (J), C7C6O (K), C7H7O• (L), C8H8O (M), and C8H9NO (N), with the
most intense ion resulting from the loss of L. The last MS2 fingerprint observed in this study arose
from the makaluvamines with a 4-ethenyl phenol substituent off the B-ring, G (8) and L (11). The MS2
fingerprints from 8 and 11 arose from the loss of E, K, L, and an unsaturated form of N (N’), with the
most intense ion resulting from the loss of K.
Once these distinct MS2 fingerprints were understood it became possible to engage in MS2-driven
dereplication and quickly identify 1–12 in Z. fuliginosa extracts. For example, 1 and 2 have the same
m/z but different fragmentation ion ratios, in that the major fragment from 1 is C and 2 is E, the same
is true of 3 and 6, where 3 generates a B fragment and 6 does not. Additionally, the loss of H and
I from the damirones (3, 5 and 6) made these readily identifiable from the makaluvamines without
substituents off the B-ring (1, 2, and 4) compounds that are otherwise similar in mass and 1H-NMR
signals. All MS2 spectra and predicted fragmentation structures are shown in the Supplementary
Materials (Figures S17 and S31) along with a summary of the makaluvamine and damirone analogs
present in some of the Z. fuliginosa extracts in the UCSC repository (Table S2).
2.3. Semi-Synthesis of Acetylated Makaluvamines and Their Identification Using 1H-NMR and MS2 Data
To determine if the makaluvamines could be candidates for further clinical development as
antibody drug conjugates (ADC) we wanted to ensure that the addition of a functional group to
the amide or N-alkyl phenol would not result in the loss of cytotoxic activity. Therefore, acetylated
derivatives were prepared from makaluvamine A (1) and J (9) (Scheme 2). The acetylation of 1
(Scheme S6) with acetic anhydride in pyridine resulted in the production of 9-N-acetyl makaluvamine
A (13). The structure of 13 was confirmed by HAESI-MS and MS2 data in addition to comparison of its
1H-NMR spectrum to that of 1. The HAESI-MS supported a molecular formula of C13H13N3O2, and
the MS2 fingerprint (Figure S29) contained a fragment corresponding to the loss of the acetyl group to
give 1. Comparison of the 1H-NMR spectra (Table 1; Figures S1 and S13) of 1 and 13 showed very little
variation with the exception of an additional singlet at δ 2.34 corresponding to the acetate methyl and
the downfield shift of the resonance for the proton at position 6 from δ 5.61 to δ 6.31. In addition to
13 the aromatized 9-N-acetyl makaluvamine B (14) were also obtained from the acetylation of 1. The
evidence for aromatization in 14 is a marked downfield shift of the resonances for protons 3 and 4
from triplets at δ 2.70 and δ 3.95 to doublets at δ 7.75 and δ 8.43, respectively (Table 1; Figures S1 and
S14). Additionally, the HAESI-MS m/z data supported a molecular formula of C13H11N3O2 and the
MS2 spectrum revealed the loss of the acetyl group resulting in a fragment with the correct m/z for
makaluvamine B.
Attempts to acetylate makaluvamine C (2) proved unsuccessful, perhaps due to the presence of
the methyl at position N-5 hindering the aromatization of the C-ring. However, the presence of the
N-5 methyl did not hinder the acetylation of the B-ring carbonyl or 4-ethyl phenol substituent as was
seen by the successful acetylation of 9 (Scheme S7), which yielded 15-O-acetyl makaluvamine J (15)
and 8,15-O-diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J (16). The structure of 15 was confirmed
by HAESI-MS and MS2 fingerprint (Figure S31). The observed m/z supports a molecular formula of
C21H22N3O3 for the cation, and the MS2 fragments observed corresponding to the loss of an acetyl
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plus J, L, M, and N. This fragmentation pattern is similar to the MS2 fingerprint of 9 (Scheme 1c),
which could only be observed if the acetyl group was on the 4-ethyl phenol substituent. Furthermore,
there was little variation between the 1H-NMR spectra of 9 and 15 aside from the appearance of the
methyl acetate singlet at δ 2.25 and the downfield shift for the resonance of protons at position 14 from
δ 6.69 to δ 7.29 (Table 1; Figures S9 and S15). The HAESI-MS of 16 confirmed a molecular formula of
C23H25N3O4 and the MS2 fingerprint yielded fragments consistent with those predicted for 9 with
acetyl groups on both the B-ring carbonyl and 4-ethyl phenol (Figure S32). This was further confirmed
by comparison of the 1H-NMR of 16 to 9 where the spectrum of 16 shows the presence of two methyl
acetate singlets at δ 2.09 and δ 2.27 and a downfield shift of the resonance for the proton at position
6 from δ 5.59 to δ 6.17 (Table 1; Figures S9 and S16). While the presence of the N-5 methyl hindered
the acetylation of 2, its presence along with the absence of the N-1 methyl appears to be critical in the
acetylation of makaluvamines containing a 4-ethyl phenol substituent, as 9 was the only one to be
successfully acetylated under the conditions used in this study.
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Scheme 2. Outcomes of the acetylation of makaluvamines A (1) and J (9).
Table 1. 1H-NMR data for makaluvamines A (1), J (9), and their acetate derivatives (13–16) prepared as
shown in Scheme 2.
Position
A (1) a A-Ac (13) a B-Ac (14) b J (9) a J-Ac (15) a J di-Ac (16) b
δH, mult, (J, Hz)
2 7.27, s 7.17, s 8.15, s 7.31, s 7.13, s 7.32, s
3 2.81, t (7.5) 2.70, t (7.5) 7.75, d (6.0) 2.92, t (7.5) 2.95, brs 3.04, t (7.5)
4 3.77, t (7.5) 3.95, t (7.5) 8.43, d (6.0) 3.89, t (7.5) 3.78, brs 3.93, t (7.5)
6 5.61, s 6.31, s 8.67, s 5.59, s 5.42, s 6.17, s
10 3.60, t (7.0) 3.63, brs 3.76, t (7.5)
11 2.83, t (7.0) 2.85, brs 2.98, t (7.5)
13 7.05, d (8.0) 7.05, d (8.0) 7.03, d (8.0)
14 6.69, d (8.0) 7.29, d (8.0) 7.31, d (8.0)
N1-Me 3.89, s 3.83, s 4.39, s
N5-Me 3.37, s 3.28, s 3.31, s
Ac 2.34, s 2.26, s 2.25, s 2.27, s 2.09, s
a 1H-NMR data measured in DMSO-d6 at 500 MHz; b 1H-NMR data measured in CD3OD at 600 MHz.
3. Discussion
This study was launched in part to explore the following questions—why are the makaluvamine
analogues first discovered in 1986 still of interest as potential therapeutics? Previous studies on the
pyrrolo[4,3,2-de]quinoline framework have identified the natural products makaluvamines C (2), H (4),
I (not shown here) or the synthetic analogue FBA-TPQ (18) as being at the top of the list of promising
compounds. We created an experimental design to add structural features missing in these natural
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products, no aryl groups at the N-R3 (Figure 3) but present in the N-R3 of the synthetic analogs.
Two recent reviews in 2009 [28] and 2016 [27] outline the prospects for further promise of the N-aryl
containing synthetic analogues. Further insights can be now added but this requires the introduction
and discussion of the additional biological screening results obtained in our work and gleaned from
the literature.
3.1. Evaluating Cytotoxicity Data for a Mini-Library of 22 Compounds
The task of IC50 assessment for the natural products isolated in this study against the
PANC-1 tumor cells line began immediately following the purification and characterization of each
pyrrolo[4,3,2-de]quinoline obtained (Figure 3). Sufficient amounts for assay screening were obtained
for analogues 1–12, and three additional semi-synthetic acetates 14–16 (Figure 3) were prepared from
makaluvamines A (1) and J (9). We attempted to obtain other related compounds, based on frameworks
shown in Figure 1 from US academic colleagues, but this was largely unsuccessful. However, a sample
of ammosamide B (17) was obtained from the NCI Molecular Targets Laboratory. Two additional
clinically used compounds etoposide and teniposide [29] were also run in the assay. Finally, literature
or unpublished data was retrieved for four molecules: FBA-TPQ (18) [25], isobatzelline C (19) [26],
discorhabdin C (20) [unpublished NCI-DTP], and gemcitabine [30]. Several insights can be gained
through closer examination of these data shown in Table 2.
Table 2. IC50 data for pyrrolo[4,3,2-de]quinolines and therapeutic standards against ovarian and
pancreatic cancer tumor cell lines.
Compound PANC-1 OVCAR-3/-5
IC50 (µM)
makaluvamine A (1) 0.45
makaluvamine C (2) 0.73 0.24 a/NT
damirone B (3) 19
makaluvamine H (4) 3.6 0.96 a/0.10 a
damirone A (5) 160
damirone D (6) 3.4
makaluvamine D (7) 0.29
makaluvamine G (8) 6.2
makaluvamine J (9) 0.054 NT/0.12
makaluvamine K (10) 0.56
makaluvamine L (11) 1.9
makaluvamine P (12) 0.3
9-N-acetyl makaluvamine B (14) 91
15-O-acetyl makaluvamine J (15) 0.081 NT/0.0086
8,15-O-diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J (16) 0.59
ammosamide B (17) 26
FBA-TBQ (18) 0.11 b 0.95 c/NT
isobatzelline C (19) 10 d




NT = Not Tested; Refs: a data obtained from Dijoux et al. [9]; b data obtained from Zhang et al. [25]; c data obtained
from Chen et al. [31]; d data obtained from Guzmán et al. [26]; e data obtained from the NCI-DTP 60 Human Tumor
Cell Lines Database; f data obtained from Li et al. [30].
The IC50 values against PANC-1 are spread out and range from 0.04 µM for teniposide a
chemotherapy drug acting as a topoisomerase II inhibitor, to 26 µM for ammosamide B (17) a cell
cycle modulator that targets myosin [19]. For the natural makaluvamines, the IC50 values ranged
from 0.054 µM for makaluvamine J (9) to 6.2 µM for makaluvamine G (8), over a 100-fold difference
in potency. As for the semi-synthetic analogs from makaluvamine A (1) not enough 9-N-acetyl
makaluvamine A (13) was obtained for IC50 determination, but the IC50 of 9-N-acetyl makaluvamine B
(14) was 91 µM, over a 200-fold reduction in potency vs. that of 1 (IC50 = 0.45 µM). There was greater
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success from one of the semi-synthetic analogs obtained from 9. The acetate derivative 15-O-acetyl
makaluvamine J (15) retained the double-digit nanomolar potency (IC50 = 0.081 µM) observed from 9,
making it a viable candidate for further clinical development as an ADC.
By contrast, the di-acetate compound 8,15-O-diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J
(16), showed triple-digit nanomolar (IC50 = 0.59 µM) potency making it not a priority for further
studies. Based on the PANC-1 IC50 dataset, makaluvamine J (9) and 15-O-acetyl makaluvamine J (15)
were selected for additional IC50 determination against the human ovarian cancer cell line OVCAR-5.
Makaluvamine J (9) had an IC50 value of 120 nM which was similar in potency to reported values for
other pyrrolo[4,3,2-de]quinoline containing compounds against OVCAR-3 and OVCAR-5 cell lines
(Table 2). Strikingly, the addition of the acetyl group on 15 resulted in a 14-fold increase in potency
over 9 with single-digit nanomolar potency of 8.6 nM against OVCAR-5. In summary, compounds 9
and 15 exhibit the most potent IC50 values relative to all other natural and synthetic makaluvamine
analogs studied to date. Obtaining a deeper understanding of the structural features responsible for
the wide range of IC50 data shown in Table 2 will be analyzed next.
3.2. Assessing Relative PANC-1 Potencies of Pyrrolo[4,3,2-de]quinolines
We believe the quantitative responses of selected compounds against the PANC-1 cell line
provide a fresh perspective to plan additional preclinical campaigns based on the makaluvamine
framework. The IC50 variations for 12 makaluvamine analogs (1, 2, 4, 7–12, 14–16), one related
halogenated compound isobatzelline C (19) [26], and the synthetic compound FBA-TPQ (18) [25]
represent an important learning set. Even though all of the entries of Figure 4 contain an ABC-ring
pyrroloiminoquinone core a wide range of PANC-1 IC50’s are represented; makaluvamine J (9) being the
most potent and 19 being relatively inactive. The substituent variations on the tricyclic core shown in
Figure 4 are key to review as follows. There are changes at: (i) R1 (CH3 or H) on the A-ring; (ii) R2 (CH3)
on the C-ring (note the + charge at the nitrogen); and (iii) R3 (H, 4-ethyl phenol substituent, 4-ethenyl
phenol substituent, 4-ethyl phenol acetate substituent, or 4-fluorobenzyl substituent). Additional
variations occur at: (iv) R4 [C(=O)CH3/acetate] on the B-ring; and (v) R5 (Cl) on the B-ring of
isobatzelline C (19) [26]. The inset panel of Figure 4 illustrates the relative impact of these substituent
changes on the in vitro IC50 Potencies [µM] against PANC-1. This impact is coded as PP with an
increase in potency indicated by “>” and a decrease in potency indicated by “<”. Three relevant SAR
structural motifs to note are (i) ABC-ring conjugation; (ii) a C-ring charge coded as “+”; and (iii) a
C-ring charge and a B-ring 4-ethyl phenol or 4-ethyl phenol acetate substituent coded as “⊕”.
The boxed panel in Figure 4 highlights that makaluvamine J (9) with code “⊕” indicating a C-ring
charge and a B-ring 4-ethyl phenol substituent is the most potent against PANC-1, exhibiting an IC50
of 0.054 µM. The designed synthetic compound, FBA-TPQ (18) [25], does not contain a positive charge
on the C-ring but does contain a 4-fluorobenzyl substituent on the B-ring, is ~50% less potent than 9
with an IC50 of 0.11 µM. 15-O-acetyl makaluvamine J (15) which only differs from 9 by the addition
of an acetyl group on the R3 substituent is only slightly less potent (PP < 1.5) than 9 with an IC50 of
0.081 µM. However, the diacetyl makaluvamine J (16) which differs from 9 in having an aromatized
B-ring and substituents at position R3 and R4, is ~10-fold less potent than 9 as it has different ABC-ring
conjugation and no positive charge on the C-ring. Additionally, when comparing 9 and makaluvamine
K (10) which only differ in their N-methyl position (9 R1 = H, R2 = CH3; 10 R1 = CH3, R2 = none
[no + charge on C-ring]) there is a 10.4-fold decrease in potency, further indicating that the presence of
the positive charge on the C-ring is important for potency.
Shown in Figure 4 are the functional group patterns required for the impressive PANC-1 potency
of 9 that has R1 = H, R2 = CH3, R3 = 4-ethyl phenol. Specifically, less potency was observed for the
substitution patterns present in makaluvamine C (2) (R1 = H, R2 = CH3, R3 = H) and makaluvamine L
(11) (R1 = H, R2 = CH3, R3 = 4-ethenyl phenol). Which resulted in reduced potency compared to 9 with
decreases in PP of 13.5 and 35.0, respectively. This highlights that the presence of an N-aryl substituent
at R3 is important for increase potency against PANC-1, but that the flexibility of that substituent is
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also important as the ethyl phenol analogs (D (7), J (9), K (10), and (P) 12) show greater potency that
the ethenyl phenol analogs (G (8), L (11)). Comparison of makaluvamines A (1) and K (10), which
only differ at R3 (1 R3 = H; 10 R3 = 4-ethyl phenol), show minimal difference in potency (PP < 1.2).
However, when comparing 1 to makaluvamine H (4) which only differ at R2 (1 no R2; 4 R2 = CH3)
a greater reduction in potency is observed (PP < 7.9). Notably, when comparing 4 to makaluvamine
P (12) which only differ at R3 (4 R3 = H; 12 R3 = 4-ethyl phenol) there is a markedly greater increase
in potency (PP > 12.3), further confirming that the presence of an N-aryl substituent is important for
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effect of makaluvamine  J  (9) at varying concentrations during continuous exposure. Other  relevant 
data  to  be  obtained  in  the  future  consists  of:  (a)  repeating  the  clonogenic  runs  on makaluvamine 
Figure 4. Impact on relative in vitro IC50 Potencies [uM] against PANC-1 (coded by PP either increasing
or (>) decreasing (<)) as a function of: (i) ABC-ring conjugation; (ii) +C-ring charge, and (iii) ⊕C-ring
charge with a B-ring N-aryl phenol or N-aryl phenol acetate substituent for pyrrolo[4,3,2-de]quinoline
containing molecules. a data obtained from Zhang et al. [25]; b data obtained from Guzmán et al. [26].
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3.3. Secondary Screening
Data summarized above (Table 2, Figure 4) led to the next steps of secondary screening on the
prioritized compound, makaluvamine J (9). The first follow-up experiments have been completed and
utilized a clonogenic assay to assess cell survival through data plotted as a concentration-survival
curve [32]. Sponge-derived compounds from our laboratory have shown a favorable profile in such
evaluations and include: fascaplysin A [33], fijianolide B [34], japlakinolide [32], and psymberin [35].
Accurate determination of the exposures required to achieve a useful in vivo therapeutic effect is
the outcome being sought through clonogenic study. Illustrated here are data measuring the cytotoxic
effect of makaluvamine J (9) at varying concentrations during continuous exposure. Other relevant
data to be obtained in the future consists of: (a) repeating the clonogenic runs on makaluvamine acetate
J (15); (b) obtaining the maximum tolerated dose (MTD) for both; and (c) assessing the pharmacokinetic
behavior of these compounds measured in both plasma and tumors, (PANC-1 and OVC-5) at the MTD,
which will be tracked through by MS2 data. Results from the clonogenic assay of makaluvamine J (9)
are shown in Figure 5. The key measurement involved determining the required time-concentration
profile to obtain a 90% kill (10% survival-S10) of tumor cells. Little toxicity to HCT-116 cells was shown
at the two hour dosing schedule; and effects observed are as follows: (i) 2 h exposure, 2S10 = 3 µg/mL
(extrapolated); (ii) 24 h exposure, 24S10 = 400 ng/mL; and (iii) 120 h exposure, 120S10 = 30 ng/mL.
These results are very promising and predict success in the follow up evaluations with PANC-1 and
OVCAR-5 tumors. At this juncture it appears that a chronic exposure for five days will be effective and
the exact therapeutics regime will depend on the MTD determination data and future pharmacokinetic
results. Once these results are in hand we will be able to fully define the necessary drug dose and
schedule required to achieve a positive in vivo therapeutic effect [36].
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Figure 5. Preclinical evaluation of makaluvamine J (9) through clonogenic dose-response evaluation
employing HCT-116 cells. Continuous exposure of the cells with 9 at different concentrations during
periods of: 2 h, 24 h, or 120 h. Efficacy is indicated when the surviving fraction is less than 0.1.
4. Material and Methods
4.1. General Experimental Procedures
Standard pulse sequences were used for all NMR experiments, which were run on either a Varian
UNITY INOVA spectrometer (600 MHz for 1H) (Agilent Technologies, Santa Clara, CA, USA) outfitted
with a 5 mm triple resonance (HCN) cold probe, a Varian spectrometer (500 MHz for 1H) equipped with
an inverse detection probe, or a Bruker spectrometer (800 MHz for 1H) (Bruker, Billerica, MA, USA)
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outfitted with a 5 mm triple-resonance (HCN) inverse cold probe. Residual solvent shifts for DMSO-d6
or CD3OD were referenced to δH 2.50 or δH 3.31, respectively. Accurate mass measurements for
molecular formula determinations were obtained on a Thermo Velos Pro electrospray ionization (ESI)
hybrid ion trap-Orbitrap mass spectrometer (Thermo Fisher, Waltham, MA, USA). All HPLC was done
in reversed-phase (RP) and utilized HPLC grade CH3CN (solvent A) and Milli-Q H2O (solvent B), both
adjusted to contain 0.1% formic acid (Thermo Fisher). The analytical LC-MS system was composed of
Waters HPLC components (i.e., solvent pumps and autosampler) and controlled by Empower software
(Waters, Milford, MA, USA). A 150 × 4.60 mm 5 µm Luna C18 column (Phenomenex, Torrance, CA,
USA) was utilized, and the system operated at a flow rate of 1 mL/min. The eluent first passed
through a photodiode array (Waters) and then was split (95:5) between an evaporative light-scattering
detector (ELSD) (SEDEX model 75) (SEDERE, Paris, Ile-de-France, France) and an ESI-time-of-flight
mass spectrometer (Applied Biosystems Mariner, Temecula, CA, USA). Column chromatography
(CC) was performed using Sephadex LH-20 (40–70 µm; Amersham Pharmacia Biotech AB, Uppsala,
Sweden) with MeOH as eluent. The preparative RP-HPLC system was composed of Waters HPLC
components (i.e., solvent pumps and gradient controller) and equipped with a 250 × 21 mm 10 µm
Synergi MAX-RP column (Phenomenex) and Pharmacia LKB UV-absorbance detector.
4.2. Animal Material
Specimens of Z. fuliginosa were collected from Papua New Guinea (PNG) (collection number
93132, 1.8 kg wet weight and 03501, 1.2 kg wet weight), Indonesia (96500; 1.2 kg wet weight), and
Fiji (97009; 1.9 kg wet weight) using SCUBA at depths between 15 and 30 m by members of the
UCSC team, a representative underwater photograph of this organism is shown in Figure 2. Two
Z. fuliginosa extracts, obtained from the NCI-DTP repository were collected from PNG (C022743-Y)
and Vanuatu (C021309-Q).
4.3. Extraction and Isolation
Z. fuliginosa samples collected by the UCSC laboratories (collection numbers 93132, 96500,
03501, and 97009) were preserved in the field and subsequently extracted using either a standard
solvent partition (SSP) or an accelerated solvent extraction (ASE) according to previously described
protocols [37]. Extracts obtained from the NCI-DTP collection (collection numbers C021309-Q and
C022743-Y) were processed according to NCI protocol [38]. Semi-pure extracted fractions that exhibited
selective bioactivity against the PANC-1 cell line were further purified.
Samples coded as 93132 (Scheme S1) and 96500 (Scheme S2) were extracted using the SSP method
and the dichloromethane-methanol fraction (coded DMM) contained bioactivity against the PANC-1
cell line. The DMM fractions were further divided into four fractions using preparative HPLC
(10:90 CH3CN:H2O to 100% CH3CN, with 0.1% formic acid, 35 min) and labeled H1-H4. From
sample 93132, the DMM-H4 fraction was subjected to CC to yield makaluvamine D (7) (2 mg) and
makaluvamine J (9) (45 mg). The DMM-H2 and DMM-H3 fractions were further purified by HPLC
(5:95 CH3CN: H2O to 60:40 CH3CN: H2O, with 0.1% formic acid) to yield makaluvamine C (2)
(2 mg) and damirone D (5) (3 mg), respectively. From sample 96500, the DMM-H2 and DMM-H3
fractions were further purified by CC to yield makaluvamine A (1) (30 mg) and damirone D (6)
(4 mg), respectively.
Two NCI-DTP extracts coded C021309-Q (Scheme S3) and C022743-Y (Scheme S4) were subjected
to CC and divided into seven fractions labeled F1–F7. Workup on the first sample C021309-Q
(Scheme S3), began with the F1 and F2 fractions and involved purification by HPLC (5:95 CH3CN:H2O
to 60:40 CH3CN:H2O, with 0.1% formic acid) to yield makaluvamine P (12) (17 mg) and 5 (11 mg),
respectively. The F3 fraction was subjected to the same HPLC conditions as fractions F1 and F2 to
give 2 (60 mg), damirone B (3) (54 mg), and makaluvamine G (8) (14 mg). The F3-H4 fraction was
further separated by HPLC (20:80 CH3CN:H2O to 35:65 CH3CN:H2O, with 0.1% formic acid) to yield
9 (20 mg) and makaluvamine K (10) (38 mg). The F4 and F5 fractions were combined and purified by
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HPLC (5:95 CH3CN:H2O to 50:50 CH3CN:H2O, with 0.1% formic acid) to yield makaluvamine L (11)
(11 mg). Workup on the second sample C022743-Y (Scheme S4) began with the F2 fraction using HPLC
(5:95 CH3CN:H2O to 60:40 CH3CN:H2O, with 0.1% formic acid) to yield 9 (53 mg). The F3 fraction was
also subjected to the same HPLC condition as F2 to give 2 (10 mg), 3 (33 mg), and 7 (21 mg). The F4
fraction was purified by HPLC (5:95 CH3CN:H2O to 50:50 CH3CN:H2O with 0.1% formic acid) to
yield 3 (15 mg) and 7 (32 mg), and the F5 fraction contained only 7 (6 mg). In total the four Z. fuliginosa
extracts generated 30 mg of 1, 72 mg of 2, 102 mg of 3, 14 mg of 5, 4 mg of 6, 61 mg of 7, 14 mg of 8,
118 mg of 9, 38 mg of 10, 11 mg of 11, 17 mg of 12.
Two additional samples 03501 and 97009 (Scheme S5) were each extracted using the ASE method
and the methanol extracts (coded XFM) were determined to have selective bioactivity against the
PANC-1 cell line. LCMS analysis was used to identify 2, makaluvamine H (4), 7, and 9 in the 03501-XFM
fraction [37] and 1, 2, and 9 in the 97009-XFM fraction. In summary 12 known compounds (1–12) shown
in Figure 3 were obtained and dereplicated by comparing their properties to those in the literature.
4.4. Compound Properties
Makaluvamine A (1): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S1;
HAESI-MS m/z [M + H]+ 202.0977 (calcd. for C11H12N3O, 202.0975).
Makaluvamine C (2): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S2;
HAESI-MS m/z M+ 202.0978 (calcd. for C11H12N3O, 202.0975).
Damirone B (3): Red-brown solid; 1H-NMR (DMSO-d6, 600 MHz) data, see Table S1 and Figure S3;
HAESI-MS m/z [M + H]+ 203.0813 (calcd. for C11H11N2O2, 203.0810).
Makaluvamine H (4): Sample obtained from our repository, brown solid; 1H-NMR (DMSO-d6, 500 MHz)
data, see Table S1 and Figure S4; HAESI-MS m/z M+ 216.1129 (calcd. for C12H14N3O, 216.1131).
Damirone A (5): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S5;
HAESI-MS m/z [M + H]+ 217.0974 (calcd. for C12H13N2O2, 217.0972).
Damirone D (6): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S6;
HAESI-MS m/z [M + H]+ 203.0817 (calcd. for C11H11N2O2, 203.0815).
Makaluvamine D (7): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S7;
HAESI-MS m/z [M + H]+ 308.1396 (calcd. for C18H18N3O2, 308.1394).
Makaluvamine G (8): Green solid; 1H-NMR (CD3OD, 600 MHz) data, see Table S1 and Figure S8;
HAESI-MS m/z M+ 334.334.1548 (calcd. for C20H20N3O2, 334.1550).
Makaluvamine J (9): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and Figure S9;
HAESI-MS m/z M+ 322.1552 (calcd. for C19H20N3O2, 322.1550).
Makaluvamine K (10): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table S1 and
Figure S10; HAESI-MS m/z [M + H]+ 322.1545 (calcd. for C19H20N3O2, 322.1550).
Makaluvamine L (11): Green solid; 1H-NMR (CD3OD, 500 MHz) data, see Table S1 and Figure S11;
HAESI-MS m/z M+ 320.1393 (calcd. for C19H18N3O2, 320.1394).
Makaluvamine P (12): Red-brown solid; 1H-NMR (CD3OD, 500 MHz) data, see Table S1and Figure S12;
HAESI-MS m/z M+ 336.1708 (calcd. for C20H22N3O2, 336.1707).
4.5. Mass Spectrometry
For each of the makaluvamines and damirones (1–12) the MS and MS2 spectra were obtained using
a Thermo Velos Pro-ESI ion trap mass spectrometer using a collision-induced dissociation energy of
35V. Spectra were collected between m/z of 100 and 500 using XCalibur software (Thermo Fisher). MS2
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spectra and predicted fragmentation structures are in the Supplementary Materials (Figures S17–S31)
and are also shown in Scheme 1.
4.6. Acetylation of Makaluvamines A (1) and J (9)
Three mg samples of 1 and 9 were dissolved in 500 µL of dried pyridine in a 10 mL scintillation
tube then 5 µL of acetic anhydride was added and the reaction solution was kept overnight at room
temperature. After the solvent was evaporated under nitrogen, the reaction mixture was purified by
HPLC (10:90 CH3CN: H2O to 60:40 CH3CN: H2O with 0.1% formic acid) to yield 13 and 14 from 1,
in addition to 15 and 16 from 9. The overall results from these reactions are shown in Scheme 2 and
Supplementary Schemes S6 and S7.
4.7. Semi-Synthetic Compound Properties
9-N-Acetyl makaluvamine A (13): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table 1 and
Figure S13; HAESI-MS m/z [M + H]+ 244.1122 (calcd. for C13H14N3O2, 244.1081).
9-N-Acetyl makaluvamine B (14): Red-brown solid; 1H-NMR (CD3OD, 600 MHz) data, see Table 1 and
Figure S14; HAESI-MS m/z [M + H]+ 242.0927 (calcd. for C13H12N3O2, 242.0924).
15-O-Acetyl makaluvamine J (15): Red-brown solid; 1H-NMR (DMSO-d6, 500 MHz) data, see Table 1 and
Figure S15; HAESI-MS m/z M+ 364.1655 (calcd. for C21H22N3O3, 364.1656).
8,15-O-Diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J (16): Colorless solid; 1H-NMR (CD3OD,
800 MHz) data, see Table 1 and Figure S16; HAESI-MS m/z [M + H]+ 408.1880 (calcd. for
C23H26N3O4, 408.1918).
4.8. Cytotoxicity Assays
The soft agar disk diffusion assay, IC50 determination, and clonogenic assay were performed as
previously described [36].
5. Conclusions
In summary, 12 previously known pyrrolo[4,3,2-de]quinoline containing makaluvamines and
damirones were obtained from Z. fuliginosa samples collected from various regions of the Indo-Pacific.
HAESI-MS2 profiling of these natural products revealed distinct fingerprint patterns that allowed for
rapid identification of these compounds in complex sponge extracts. All 12 of these natural products,
in addition to three acetylated makaluvamine derivatives, were assayed for cytotoxic activity against
the PANC-1 cell line. Data retrieved from this assay identified three structural motifs that were
important in maximizing potency against the PANC-1 cell line: (i) conjugation of the core ABC-ring;
(ii) a positive charge on the C-ring; and (iii) the presence of a 4-ethyl phenol or 4-ethyl phenol acetate
substituent off the B-ring. Makaluvamine J (9) and 15-O-acetyl makaluvamine J (15) containing all
three of these motifs and exhibited the greatest nanomolar potency against the PANC-1 and OVCAR-5
cell lines. Previous studies investigating the cytotoxicity of pyrrolo[4,3,2-de]quinoline containing
compounds for anticancer drug leads have primarily focused on makaluvamines C (2), H (4), and I, or
the synthetic analog FBA-TPQ (18). No one to date has looked at makaluvamine J (9) as a promising
anti-cancer drug lead, therefore we are going forward with makaluvamine J (9) and 15-O-acetyl
makaluvamine J (15) for future pre-clinical development and results will be reported in the near future.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/4/98/s1,
Schemes S1–S5: Isolation schemes for compounds 1–12, Figures S1–S16: 1H-NMR spectra for compounds 1–16,
Table S1: 1H-NMR data (500/600 MHz) for the makaluvamines (1, 2, 4, 7–12) and damirones (3, 5, 6) in DMSO-d6,
Figures S17–S31: MS2 spectra for compounds 1–16, Schemes S6 and S7: The acetylation reaction of makaluvamine
A (1) and J (9), Table S2: HAESI-MS2 detection of 1–12 in Z. fuliginosa extracts.
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